Epstein-Barr virus latent membrane protein 2 (LMP2) peptide-HLA class I complex (EBV LMP2-HLA-I)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide-HLA class I complex is a primary target for immunotherapeutic intervention in EBV-associated malignancies, such as nasopharyngeal carcinoma and certain lymphomas (Taylor et al., 2015, PubMed: 25403441). LMP2 is a transmembrane protein that maintains viral latency and is consistently expressed in EBV-infected cells during latency stages II and III (UniProt P13285). Within these cells, LMP2 is proteolytically processed into immunogenic peptides, such as the HLA-A*02:01-restricted epitope CLGGLLTMV, which are then presented on the cell surface by HLA class I molecules (Lee et al., 1997, PubMed: 9151704). These complexes are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, making them ideal targets for adoptive cell therapies like EBV-specific T cells (e.g., Tabelecleucel) and TCR-engineered T cells (Prockop et al., 2020, PubMed: 32814015). Therapeutic strategies aim to enhance the immune system's ability to identify and eliminate cells presenting these complexes, thereby controlling viral spread and inducing tumor regression. However, challenges such as HLA polymorphism and the potential for viral immune evasion through HLA downregulation remain significant hurdles in the broad application of these therapies (Hui et al., 2013, PubMed: 23341461).

Other names

EBV LMP2-pMHC complexLMP2-HLA complexEpstein-Barr virus LMP2 antigen-MHC complexLMP2A/B-HLA class I complexEBV LMP2-peptide-MHC

Recognition of the specific viral peptide-HLA complex by the T-cell receptor (TCR) of CD8+ cytotoxic T lymphocytes, triggering the release of perforins and granzymes to induce apoptosis in EBV-infected or malignant cells (Lee et al., 1997, PubMed: 9151704).